J Refract Surg. 2021 May;37(5):304-311. doi: 10.3928/1081597X-20210210-02. Epub 2021 May 1.
To evaluate refractive and visual outcomes of small incision guided human cornea treatment (SmartSight; SCHWIND eye-tech-solutions) in the treatment of myopic astigmatism with the use of a new femtosecond laser system.
This retrospective, observational case series study included 104 eyes of 56 patients who underwent SmartSight to correct myopic astigmatism and completed the 3-month follow-up. Procedures were performed with a SCHWIND ATOS femtosecond laser.
Preoperatively, mean manifest spherical equivalent refraction was -6.12 ± 1.99 diopters (D) (range: -3.00 to -11.50 D) and astigmatism was 1.02 ± 0.56 D (range: 0.25 to 2.75 D). Three months postoperatively, it was +0.47 ± 0.32 D (range: -0.75 to +1.00 D) and 0.27± 0.22 D (range: 0.00 to 0.75 D), respectively (both < .05). Spherical equivalent correction within ±0.50 D was achieved in 62 eyes (60%), and cylindrical correction in 90 eyes (87%). Preoperative corrected distance visual acuity (CDVA) was 20/20 or better in 94 eyes (90%) and postoperative uncorrected distance visual acuity was 20/20 or better in 96 eyes (92%). No eye lost two or more Snellen lines of CDVA.
Myopic astigmatism correction with Smart-Sight provided good results for efficacy, safety, predictability, and visual outcomes in the first 3 months of follow-up. .
评估使用新型飞秒激光系统治疗近视散光的小切口引导人眼角膜治疗(SmartSight;SCHWIND eye-tech-solutions)的屈光和视觉效果。
这是一项回顾性、观察性病例系列研究,纳入了 56 例 104 只眼,这些患者接受 SmartSight 治疗近视散光,并完成了 3 个月的随访。手术采用 SCHWIND ATOS 飞秒激光进行。
术前,平均显微微观等效球镜屈光度为-6.12±1.99 屈光度(D)(范围:-3.00 至-11.50 D),散光为 1.02±0.56 D(范围:0.25 至 2.75 D)。术后 3 个月,等效球镜屈光度为+0.47±0.32 D(范围:-0.75 至+1.00 D)和 0.27±0.22 D(范围:0.00 至 0.75 D),均(均<0.05)。62 只眼(60%)实现了等效球镜屈光度在±0.50 D 以内的矫正,90 只眼(87%)实现了圆柱镜屈光度的矫正。术前矫正视力(CDVA)为 20/20 或更好的有 94 只眼(90%),术后未矫正视力为 20/20 或更好的有 96 只眼(92%)。没有一只眼丧失两排或更多的 CDVA 视力。
在随访的头 3 个月,Smart-Sight 治疗近视散光的效果、安全性、可预测性和视觉效果良好。